Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection (COVERAGE-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04920838

Recruitment Status : Recruiting

First Posted : June 10, 2021

Last Update Posted : January 31, 2023

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

University of Bordeaux

Institut National de la Santé Et de la Recherche Médicale, France

PACCI Program

Alliance for International Medical Action

Centre Muraz

Barcelona Institute for Global Health

Information provided by (Responsible Party):

ANRS, Emerging Infectious Diseases

Study Description

Brief Summary:

Coverage Africa is a nested study in the large Anticov platform trial that aims to generate data on new early treatment strategies for mild/moderate COVID-19 patients in resource-limited-settings to reduce the number progressing to severe forms requiring hospitalization, thereby relieving the burden on health care systems and contributing to "flattening the curve" in contexts where none pharmaceutical intervention such as quarantine are difficult to implement in large urban settings. Treating early when the virus is still present might also limit transmission. Coverage Africa will be conducted in Guinea and Burkina Faso.

The main objective is to conduct an open-label, multicenter, randomized, adaptive platform trial to test the safety and efficacy of several marketed products, including antiviral therapies versus control in mild/moderate of coronavirus disease 2019 (Covid-19) in resource-limited-settings.

The study aims to recruit 600 patients in both countries, one site in Guinea and two sites in Burkina Faso.

The current assessed treatments are now the association of Fluoxétine/Budésonide compared with a control arm: paracetamol.

The adaptive design trial will allow for the removal of drugs, or the addition of new study arms when new data becomes available. Data on the primary efficacy parameters and safety will be integrated with the primary endpoint based on an oxygen saturation percentage (SpO2) ≤ 93% or death within 14 days after randomization to treatment, including death for any reason.

Study will run until August 2022. However, with the proposed adaptive design, the study could also be interrupted for success earlier than planned with the identification of a treatment that significantly reduces hospitalization rate as evidence by results from the primary endpoint.

Condition or disease	Intervention/treatment	Phase
Covid19 Covid19 Drug Treatment Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV2 Infection	Drug: Nitazoxanide and Ciclésonide Drug: Telmisartan 20Mg Oral Tablet Drug: Paracetamol Drug: Fluoxétine and Budésonide	Phase 2 Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	600 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	This is a multicentre, multiple country, randomised, open-label, adaptive, platform clinical study aiming to determine the efficacy and safety of various treatment regimens for prevention of the need for hospitalisation for specialised care due to severe progression of COVID-19. The study is designed with the ability to incorporate the adding or dropping of treatment arms and that will include similar inclusion and non-inclusion criteria, the same primary and secondary endpoints, common data entry procedures, a shared database and a single statistical methodology for analysis of the primary endpoint.
Masking:	None (Open Label)
Masking Description:	Investigators and all the staff in clinical sites will not be masked. Data manager and statician will not be masked too. However, the sponsor will be masked.
Primary Purpose:	Treatment
Official Title:	Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)
Actual Study Start Date :	April 12, 2021
Estimated Primary Completion Date :	August 2023
Estimated Study Completion Date :	August 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COVID-19 (Coronavirus Disease 2019) End of Life Issues

Genetic and Rare Diseases Information Center resources: Acute Graft Versus Host Disease Severe Acute Respiratory Syndrome

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Paracetamol Patients in this arm will receive paracetamol during 14 days	Drug: Paracetamol Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses. Duration of treatment: up to 14 days
Experimental: Nitazoxanide and Ciclésonide Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days	Drug: Nitazoxanide and Ciclésonide Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
Experimental: Telmisartan Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days	Drug: Telmisartan 20Mg Oral Tablet 20 mg tablet daily
Experimental: Fluoxétine and Budésonide Patients in this arm will receive the combination of Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2*400 mcg) during 7 days	Drug: Fluoxétine and Budésonide Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.

Outcome Measures

Primary Outcome Measures :

SpO2 ≤ 93% within 14 days [ Time Frame: From inclusion (day 0) to day 14. ]
Percentage of participant presenting an oxygen saturation percentage (SpO2) ≤ 93% or death within 14 days after randomization to treatment.
Death within 14 days [ Time Frame: From inclusion (day 0) to day 14. ]
Percentage of participant dead within 14 days after randomization to treatment, including death for any reason.

Secondary Outcome Measures :

Death within 28 days [ Time Frame: From inclusion (day 0) to day 28. ]
Percentage of participant dead within 28 days after randomization to treatment, including death for any reason.
Occurence of at least one grade 3 or 4 clinical or biological adverse event within 14 days [ Time Frame: From inclusion (day 0) to day 14. ]
Occurence of at least one grade 3 or 4 clinical or biological adverse event within 14 days
Number of hospitalizations due to severe progression [ Time Frame: From inclusion (day 0) to day 28. ]
Hospitalisation due to aggravation of COVID-19, including hospitalisation's reason as described below
- Request of mechanical ventilation and/or Intensive Care Unit (ICU)
- Non-ICU hospitalisation, requiring supplemental oxygen
- Non-ICU hospitalisation, not requiring supplemental oxygen

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adults 18 years of age at the time of screening or >= 40 years and presenting at least one comorbidity : high blood pressure; a known obesity and/ or a known and treated diabete.
SARS-CoV-2 infection confirmed by molecular biology (RT-PCR on a nasopharyngeal or oropharyngeal swab) or by antigen test validated in the country according to national guidelines
A viral syndrome with or without uncomplicated pneumonia, defined as blood oxygen saturation level (SpO2) >=94%.
Mild Covid-19 symptoms with an onset < 7 days before inclusion.
Signed written consent from the patient or his/her representative.
No need an oxygen therapy according to international guidelines (WHO Progression Scale, grade 2 to 4)
Accepting and having the ability to be reached by telephone throughout the study.
Having designated a contact person who can be contacted in case of emergency.
Accepted to be reached by phone along throughout the study

Exclusion Criteria:

Blood oxygen saturation level (SpO2) < 94%.
Known hypersensitivity to investigational products
Chronic treatment with inhaled corticosteroids (up to 30 days)
Known history of renal or hepatic failure
Abnormal physical examination findings:
- respiratory rate < 25 per minute;
- Clinical hypotension with associated signs justifying hospital care
Feeling unwell for more than 7 days prior to screening.
End-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months.
For any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use.
Patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs
Known history of long QT syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation)
Unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the Investigator or cannot use an inhalation chamber.
Any other reason that makes it impossible to monitor the patient during the study.
Enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study IPs or are contraindicated as concomitant therapy within the last 3 months prior to screening

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04920838

Contacts

Layout table for location contacts

Contact: Olivier Marcy, Dr	+33 557 57 47 23	olivier.marcy@u-bordeaux.fr
Contact: Anthony L'Hostellier	+33 557 57 47 23	anthony.lhostellier@u-bordeaux.fr

Locations

Layout table for location information

Burkina Faso
Centre Muraz/INSP	Recruiting
Bobo-Dioulasso, Burkina Faso
Contact: Armel Poda, Pr. 65314949 ext +226 armelpoda@yahoo.fr
Contact: Apoline Sondo, Pr 70077198 ext +226 sondoapoline@yahoo.fr
Guinea
Centre de traitement des maladies à tendance épidémique de Gbessia	Suspended
Conakry, Guinea

Sponsors and Collaborators